



ASX ANNOUNCEMENT

Interest and Facility Fees Update

8 September 2025 – Cann Group Limited (ASX: CAN) (“**Cann**” or the “**Company**”) advises that, following recent discussions and as expected, it has received a Letter of Non-Waiver from National Australia Bank Limited (“**NAB**”) in relation to Cann’s non-payment of quarterly and six-monthly interest and facility fees owed on the Company’s Property Development Facility and Working Capital Facility (respectively) totalling \$1,378,152 which were due late August 2025.

Importantly, NAB has confirmed, that whilst reserving its rights and remedies, it will not be taking any action at this time.

As announced on 29 August 2025, the Company continues to engage constructively with NAB and other financiers in relation to its financing arrangements, including the aforementioned interest and facility fees, and expects to update the market by the end of September 2025.

Authorised for release by Board of Directors, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com

For personal use only